VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Men or non-pregnant women of any ethnic background │ Men or non-pregnant women of any ethnic background │     100 │
│ between the age of 18 and 45 years old             │ between the age of 18 and 45 years old             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects must be non-smokers (must have refrained  │ Subjects must be non-smokers (must have refrained  │     100 │
│ from the use of nicotine-containing substances,    │ from the use of nicotine-containing substances,    │         │
│ including tobacco products (e.g. cigarettes,       │ including tobacco products (e.g. cigarettes,       │         │
│ cigars, chewing tobacco, gum, patch or electronic  │ cigars, chewing tobacco, gum, patch or electronic  │         │
│ cigarettes) over the previous 2 months and are not │ cigarettes) over the previous 2 months and are not │         │
│ currently using tobacco products                   │ currently using tobacco products                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Provide written informed consent before initiation │ Provide written informed consent before initiation │     100 │
│ of any study procedures                            │ of any study procedures                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Available for follow-up for the planned duration   │ Available for follow-up for the planned duration   │     100 │
│ of the study                                       │ of the study                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able to communicate well with the investigators    │ Able to communicate well with the investigators    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able to adhere to the study protocol schedule,     │ Able to adhere to the study protocol schedule,     │     100 │
│ study restrictions and examination schedule        │ study restrictions and examination schedule        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects deemed to be healthy as judged by the     │ Subjects deemed to be healthy as judged by the     │     100 │
│ Medically Accountable Investigator (MAI) and       │ Medically Accountable Investigator (MAI) and       │         │
│ determined by medical history, physical            │ determined by medical history, physical            │         │
│ examination and medication history                 │ examination and medication history                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects have no history of the following: ongoing │ Subjects have no history of the following: ongoing │     100 │
│ acute or intermittent pain, postoperative pain,    │ acute or intermittent pain, postoperative pain,    │         │
│ respiratory compromise, acute or severe asthma, or │ respiratory compromise, acute or severe asthma, or │         │
│ constipation (less than 1 bowel movement every 2   │ constipation (less than 1 bowel movement every 2   │         │
│ days)                                              │ days)                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Negative urine drug screening test at the time of  │ Negative urine drug screening test at the time of  │     100 │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have normal screening laboratories for white blood │ Have normal screening laboratories for white blood │     100 │
│ cells (WBC), hemoglobin (Hgb), platelets, sodium,  │ cells (WBC), hemoglobin (Hgb), platelets, sodium,  │         │
│ potassium, chloride, bicarbonate, blood urea       │ potassium, chloride, bicarbonate, blood urea       │         │
│ nitrogen (BUN), creatinine, ALT (liver function),  │ nitrogen (BUN), creatinine, ALT (liver function),  │         │
│ AST (liver function) and bilirubin                 │ AST (liver function) and bilirubin                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have normal screening laboratories for urine       │ Have normal screening laboratories for urine       │     100 │
│ protein and urine glucose                          │ protein and urine glucose                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects must be of non-childbearing        │ Female subjects must be of non-childbearing        │     100 │
│ potential (as defined as surgically sterile \[i.e. │ potential (as defined as surgically sterile [i.e.  │         │
│ history of hysterectomy or tubal ligation\] or     │ history of hysterectomy or tubal ligation] or      │         │
│ postmenopausal for more than 1 year \[no bleeding  │ postmenopausal for more than 1 year [no bleeding   │         │
│ for 12 consecutive months\], or if of childbearing │ for 12 consecutive months], or if of childbearing  │         │
│ potential must be non-pregnant at the time of      │ potential must be non-pregnant at the time of      │         │
│ enrollment and on the morning of the first day of  │ enrollment and on the morning of the first day of  │         │
│ each study session, and must agree to use hormonal │ each study session, and must agree to use hormonal │         │
│ or barrier birth control such as implants,         │ or barrier birth control such as implants,         │         │
│ injectables, combined oral contraceptives, some    │ injectables, combined oral contraceptives, some    │         │
│ intrauterine devices (IUDs), sexual abstinence or  │ intrauterine devices (IUDs), sexual abstinence or  │         │
│ a vasectomized parter                              │ a vasectomized parter                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Agrees not to participate in another clinical      │ Agrees not to participate in another clinical      │     100 │
│ study/trial during the study period or to          │ study/trial during the study period or to          │         │
│ participate in an investigational drug study for   │ participate in an investigational drug study for   │         │
│ at least one month after last study session        │ at least one month after last study session        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Agrees not to donate blood to a blood bank         │ Agrees not to donate blood to a blood bank         │     100 │
│ throughout participation in the study and for at   │ throughout participation in the study and for at   │         │
│ least 3 months after last study day                │ least 3 months after last study day                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have a normal ECG; must not have the following to  │ Have a normal ECG; must not have the following to  │     100 │
│ be acceptable: pathologic Q wave abnormalities,    │ be acceptable: pathologic Q wave abnormalities,    │         │
│ significant ST-T wave changes, left ventricular    │ significant ST-T wave changes, left ventricular    │         │
│ hypertrophy, right bundle branch block, left       │ hypertrophy, right bundle branch block, left       │         │
│ bundle branch block. (sinus rhythm is between      │ bundle branch block. (sinus rhythm is between      │         │
│ 55-100 beats per minute)                           │ 55-100 beats per minute)                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Temperature 35-37.9°C (95-100.3°F)                 │ Temperature 35-37.9°C (95-100.3°F)                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systolic blood pressure 90-140 mmHg                │ Systolic blood pressure 90-140 mmHg                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diastolic blood pressure 60-90 mmHg                │ Diastolic blood pressure 60-90 mmHg                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Heart rate 55-100 beats per minute                 │ Heart rate 55-100 beats per minute                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Respiration rate 12-18 breaths per minute          │ Respiration rate 12-18 breaths per minute          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are pregnant, lactating or breast        │ Women who are pregnant, lactating or breast        │     100 │
│ feeding or have a positive serum pregnancy test at │ feeding or have a positive serum pregnancy test at │         │
│ enrollment or positive urine pregnancy test on the │ enrollment or positive urine pregnancy test on the │         │
│ morning of the first day of any study session      │ morning of the first day of any study session      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Smokers (current use or use over the previous 2    │ Smokers (current use or use over the previous 2    │     100 │
│ months of nicotine-containing substances,          │ months of nicotine-containing substances,          │         │
│ including tobacco products (e.g. cigarettes,       │ including tobacco products (e.g. cigarettes,       │         │
│ cigars, chewing tobacco, gum, patch or electronic  │ cigars, chewing tobacco, gum, patch or electronic  │         │
│ cigarettes)                                        │ cigarettes)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in any ongoing investigational drug  │ Participation in any ongoing investigational drug  │     100 │
│ trial/study or clinical drug trial/study           │ trial/study or clinical drug trial/study           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of chronic obstructive pulmonary disease   │ History of chronic obstructive pulmonary disease   │     100 │
│ or cor pulmonale, or substantially decreased       │ or cor pulmonale, or substantially decreased       │         │
│ respiratory reserve, hypoxia, hypercapnia or pre-  │ respiratory reserve, hypoxia, hypercapnia or pre-  │         │
│ existing respiratory depression                    │ existing respiratory depression                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active positive Hepatitis B, C and HIV serologies  │ Active positive Hepatitis B, C and HIV serologies  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Positive urine drug screening test                 │ Positive urine drug screening test                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any prescription medication during the      │ Use of any prescription medication during the      │     100 │
│ session 0 to 30 days or over-the counter           │ session 0 to 30 days or over-the counter           │         │
│ medication e.g. antihistamines or topical          │ medication e.g. antihistamines or topical          │         │
│ corticosteroids (vitamin, herbal supplements and   │ corticosteroids (vitamin, herbal supplements and   │         │
│ birth control medications not included) during the │ birth control medications not included) during the │         │
│ session 0 to 3 days before entry to the study      │ session 0 to 3 days before entry to the study      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of medications or treatments that would        │ Use of medications or treatments that would        │     100 │
│ significantly influence or exaggerate responses to │ significantly influence or exaggerate responses to │         │
│ the test product or that would alter inflammatory  │ the test product or that would alter inflammatory  │         │
│ or immune response to the product or agents deemed │ or immune response to the product or agents deemed │         │
│ to be immunosuppressive as determined by physician │ to be immunosuppressive as determined by physician │         │
│ investigator with 72 hours prior to dosing (e.g.   │ investigator with 72 hours prior to dosing (e.g.   │         │
│ antihistamines, systemic or topical                │ antihistamines, systemic or topical                │         │
│ corticosteroids (within 3 weeks prior to dosing),  │ corticosteroids (within 3 weeks prior to dosing),  │         │
│ cyclosporine, tacrolimus, cytotoxic drugs, immune  │ cyclosporine, tacrolimus, cytotoxic drugs, immune  │         │
│ globulin, Bacillus Calmette-Guerin (BCG),          │ globulin, Bacillus Calmette-Guerin (BCG),          │         │
│ monoclonal antibodies, radiation therapy)          │ monoclonal antibodies, radiation therapy)          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of monoamine oxidase inhibitors 21 days prior  │ Use of monoamine oxidase inhibitors 21 days prior  │     100 │
│ to study                                           │ to study                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of mixed agonist/antagonist (such as   │ Current use of mixed agonist/antagonist (such as   │     100 │
│ pentazocine, nalbuphine or butorphanol) and        │ pentazocine, nalbuphine or butorphanol) and        │         │
│ partial agonist (buprenorphine) analgesics         │ partial agonist (buprenorphine) analgesics         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of anticholinergics or other           │ Current use of anticholinergics or other           │     100 │
│ medications with anticholinergic activity          │ medications with anticholinergic activity          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Consumption of beverages containing alcohol,       │ Consumption of beverages containing alcohol,       │     100 │
│ grapefruit juice, Seville oranges, or quinine      │ grapefruit juice, Seville oranges, or quinine      │         │
│ (e.g. tonic water) or foods containing poppy seeds │ (e.g. tonic water) or foods containing poppy seeds │         │
│ in the last 72 hours                               │ in the last 72 hours                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Donation or loss of greater than one pint of blood │ Donation or loss of greater than one pint of blood │     100 │
│ within 60 days of entry to the study               │ within 60 days of entry to the study               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any prior serious adverse reaction or              │ Any prior serious adverse reaction or              │     100 │
│ hypersensitivity to fentanyl, morphine, codeine,   │ hypersensitivity to fentanyl, morphine, codeine,   │         │
│ hydrocodone, hydromorphone, oxycodone,             │ hydrocodone, hydromorphone, oxycodone,             │         │
│ oxymorphone, naltrexone or naloxone or any of the  │ oxymorphone, naltrexone or naloxone or any of the  │         │
│ inactive ingredients in the TDDS (polyester/ethyl  │ inactive ingredients in the TDDS (polyester/ethyl  │         │
│ vinyl acetate, polyacrylate adhesive, silicone     │ vinyl acetate, polyacrylate adhesive, silicone     │         │
│ adhesive, dimethicone NF, or polyolefin)           │ adhesive, dimethicone NF, or polyolefin)           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have a diagnosis of schizophrenia or other major   │ Have a diagnosis of schizophrenia or other major   │     100 │
│ psychiatric diagnosis or mental illness (e.g.      │ psychiatric diagnosis or mental illness (e.g.      │         │
│ major depression)                                  │ major depression)                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medical history of personal drug or alcohol        │ Medical history of personal drug or alcohol        │     100 │
│ addiction or abuse                                 │ addiction or abuse                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any condition that would, in the opinion of the    │ Any condition that would, in the opinion of the    │     100 │
│ MAI, place the subject at an unacceptable risk of  │ MAI, place the subject at an unacceptable risk of  │         │
│ injury or render the subject unable to meet the    │ injury or render the subject unable to meet the    │         │
│ requirements of the protocol                       │ requirements of the protocol                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inability to communicate or cooperate with the     │ Inability to communicate or cooperate with the     │     100 │
│ investigators                                      │ investigators                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject has an obvious difference in skin color    │ Subject has an obvious difference in skin color    │     100 │
│ between arms or the presence of a skin condition,  │ between arms or the presence of a skin condition,  │         │
│ excessive hair at the application site (upper      │ excessive hair at the application site (upper      │         │
│ arm), sunburn, raised moles and scars, open sore,  │ arm), sunburn, raised moles and scars, open sore,  │         │
│ scar tissue, tattoo, or coloration that would      │ scar tissue, tattoo, or coloration that would      │         │
│ interfere with placement of test articles, skin    │ interfere with placement of test articles, skin    │         │
│ assessment, or reactions to drug                   │ assessment, or reactions to drug                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Failure to pass opioid dependence challenge test   │ Failure to pass opioid dependence challenge test   │     100 │
│ on the first day study day of any study session    │ on the first day study day of any study session    │         │
│ (i.e., before taking the first dose of naltrexone  │ (i.e., before taking the first dose of naltrexone  │         │
│ hydrochloride). Each subject will be injected      │ hydrochloride). Each subject will be injected      │         │
│ subcutaneously with naloxone hydrochloride (0.8 mg │ subcutaneously with naloxone hydrochloride (0.8 mg │         │
│ injection) and will be observed for 45 minutes for │ injection) and will be observed for 45 minutes for │         │
│ signs and symptoms of opioid withdrawal            │ signs and symptoms of opioid withdrawal            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Within 4 weeks prior to dosing, use of medications │ Within 4 weeks prior to dosing, use of medications │     100 │
│ or treatments that would significantly influence   │ or treatments that would significantly influence   │         │
│ or exaggerate responses to the test product or     │ or exaggerate responses to the test product or     │         │
│ that would alter inflammatory or immune response   │ that would alter inflammatory or immune response   │         │
│ to the product or agents deemed to be              │ to the product or agents deemed to be              │         │
│ immunosuppressive as determined by physician       │ immunosuppressive as determined by physician       │         │
│ investigator                                       │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who are within their ideal body weight    │ Subjects who are within their ideal body weight    │      98 │
│ (BMI between \>17 and ≤28 kg/m2)                   │ (BMI between >17 and =28 kg/m2)                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 45 Years │ Men or non-pregnant women of any ethnic background │      38 │
│                                   │ between the age of 18 and 45 years old             │         │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Positive urine drug screening test                 │      39 │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have normal vital signs           │ Have normal screening laboratories for urine       │      41 │
│                                   │ protein and urine glucose                          │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 95.91111111111111
OverAll Ratio: 97.45555555555555
